Sankalp Arora/X
May 24, 2025, 07:00
Sankalp Arora: Sharing our ASCO25 Abstract – Relapse Mechanisms After FLT3i therapy in Frontline AML
Sankalp Arora, Hematology/Medical Oncology Fellow at MD Anderson Cancer Center, shared in a post on X:
“Sharing our ASCO25 abstract: relapse mechanisms after FLT3i rx in frontline AML.
FLT3 loss and emergent DNA methylation/RAS-MAPK/WT1 mutations were common at relapse. Post SCT relapses were less likely to be driven by emergent mutations.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 24, 2025, 20:49
Jul 24, 2025, 20:37
Jul 24, 2025, 20:05
Jul 24, 2025, 19:59
Jul 24, 2025, 19:29